Is Medicamen Biotec overvalued or undervalued?

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting high valuation concerns. The company is currently considered overvalued based on its elevated metrics. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry averages.
In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Divi's Lab's 69.65, while its EV to EBITDA ratio is notably higher than Sun Pharma's 24.09 and lower than Divi's Lab's 52.35. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the perception of overvaluation.